{"id":1574,"date":"2003-06-01T12:01:00","date_gmt":"2003-06-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie"},"modified":"2003-06-01T12:01:00","modified_gmt":"2003-06-01T10:01:00","slug":"lipidsenker-bei-hypertonikern-die-ascot-lla-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie","title":{"rendered":"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie"},"content":{"rendered":"<p>Da Statine zu den meist verordneten und die Gesundheits-Budgets vieler L\u00e4nder am meisten belastenden Medikamenten geh\u00f6ren, sind neue gut durchgef\u00fchrte Studien an spezifischen Patientenkollektiven sehr willkommen. Da fast alle diese Studien von den das jeweilige Statin herstellenden oder vermarktenden Firmen gesponsert werden, besteht deren Motivation f\u00fcr das Sponsoring nat\u00fcrlich prinzipiell in dem Wunsch, die Indikationen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Da Statine zu den meist verordneten und die Gesundheits-Budgets vieler L\u00e4nder am meisten belastenden Medikamenten geh\u00f6ren, sind neue gut durchgef\u00fchrte Studien an spezifischen Patientenkollektiven sehr willkommen. Da fast alle diese Studien von den das jeweilige Statin herstellenden oder vermarktenden Firmen gesponsert werden, besteht deren Motivation f\u00fcr das Sponsoring nat\u00fcrlich prinzipiell in dem Wunsch, die Indikationen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[800,60,3688,1046,324,451,449,71,180,68,455,453,325,498,456,65,2523,801,56,443],"class_list":["post-1574","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-allhat-llt-studie","tag-apoplektischer-insult","tag-ascot-lla-studie","tag-atorvastatin","tag-blutdruck","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-herzinfarkt","tag-herzinsuffizienz","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-hypertonie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-number-needed-to-treat","tag-pravastatin","tag-schlaganfall","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1574"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1574\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}